|
WO2015051484A1
|
|
Preparation of hydroxy-benzylbenzene derivatives
|
|
US2013267694A1
|
|
Process for the preparation of benzylbenzene SGLT2 inhibitors
|
|
CN104334568A
|
|
Process for preparation of benzylbenzene sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors
|
|
WO2013152476A1
|
|
Process for the preparation of benzylbenzene sglt2 inhibitors
|
|
WO2011163231A2
|
|
Combination therapy for the treatment of diabetes
|
|
US2011077212A1
|
|
Therapeutic uses of sglt2 inhibitors
|
|
US2011021507A1
|
|
Inhibiting antipsychotic-induced weight gain
|
|
WO2011153712A1
|
|
Crystalline form of benzylbenzene sglt2 inhibitor
|
|
SG193168A1
|
|
Processes for the preparation of sglt2 inhibitors
|
|
TW201010696A
|
|
Deuterated benzylbenzene derivatives and methods of use
|
|
NZ604558A
|
|
Deuterated benzylbenzene derivatives and methods of use
|
|
EP2230907A1
|
|
Benzylphenyl cyclohexane derivatives and methods of use
|
|
BRPI0809607A2
|
|
Compound, pharmaceutical composition, pharmaceutical combination, and method for treating a disease
|
|
US2008182802A1
|
|
Spiroheterocyclic glycosides and methods of use
|
|
US2008108825A1
|
|
Compounds for treatment of inflammation, diabetes and related disorders
|
|
US2008103302A1
|
|
Compounds for treatment of inflammation, diabetes and related disorders
|
|
CN101472476A
|
|
Treating obesity with muscarinic receptor M1 antagonists
|
|
US2007293480A1
|
|
Treating psychological conditions using muscarinic receptor M1 antagonists
|
|
EP2019679A2
|
|
Glucose transport inhibitors and methods of use
|
|
UA85069C2
|
|
Combined medicinal therapy for obesity treatment
|
